Study design: Systematic literature review for primary data using prede®ned inclusion, exclusion and validity criteria. Primary outcome measure was standardised neurological examination or neurological function. Secondary outcomes; acute mortality, early morbidity. Objectives: To access the literature available to clinicians systematically and evaluate the evidence for an eect of high dose methylprednisolone (MPSS) on neurological improvement following acute spinal cord injury (ACSI). Methods: Information retrieval was based on Medline search (1966 through December 1999) using the strategy`spinal cord injury' and`methylprednisolone' (or`dexamethasone') with no other restrictions. Primary data publications using high dose steroids given within 12 h following spinal cord injury and reporting outcome measures separately for steroid and nonsteroid treated groups were selected. Evaluation followed the guides of Guyatt et al 7 (for the Evidence Based Working Group in Canada). Studies with questionable validity were excluded. Level of evidence and treatment recommendation utilised the Canadian Task Force on the Periodic Health Examination criteria. 6 Experimental spinal cord injury studies on larger animals were included; small mammal experiments were considered beyond evaluation. Results: Three clinical trials and six cohort study publications were found to satisfy the review criteria. The evidence they provide supports`the recommendation that the manoeuvre (high dose methylpredisolone) be excluded from consideration as an intervention for the condition' 10 (acute spinal cord injury). Twelve larger animal publications were detailed. Validity and the functional signi®cance of results was of concern in many. The weight of evidence lay with those studies demonstrating no de®nite eect of MPSS on functional outcome. In cat experiments with higher level cord damage, deaths in the MPSS treated groups were notable. Conclusion: The evidence produced by this systematic review does not support the use of high dose methylprednisolone in acute spinal cord injury to improve neurological recovery. A deleterious eect on early mortality and morbidity cannot be excluded by this evidence. Spinal Cord (2000) 38, 273 ± 286
Introduction
Pharmacological interventions to improve outcome following acute spinal cord injury (ASCI) are theoretically attractive. Administration of drugs within hours of injury is possible in practice, especially with organised systems of trauma care. Intravenous high dose methylprednisolone given within 8 h of injury has been advocated since the initial publication from the second American National Acute Spinal Cord Injury Study (NASCIS 2) . 1 This practice is based on conclusions derived from a selected post hoc subgroup analysis in one clinical trial.
Current recommendations on reviewing the evidence for clinical ecacy of an intervention consistently advise caution in applying results from non-randomised groups of patients. 2 ± 5 The practice now promoted involves a thorough search for relevant studies, appropriate inclusion criteria, adequate assessment of the validity of included studies and de®ned frameworks for interpreting results and making practice recommendations. 6 ± 8 The objective of this review is to access the available literature systematically and evaluate the evidence for an eect of high dose methylprednisolone (MPSS) on neurological improvement following traumatic spinal cord injury (SCI).
Methods
Data identi®cation/information retrieval (a) Electronic database search: MEDLINE software (1966 through December 1999) was searched using the strategy`spinal cord injury' and`methylprednisolone' or`spinal cord injury' and`dexamethasone' with no other restrictions. The data set was manually searched by title and abstract on screen and references selected. These printed citations were re-reviewed and the full article obtained where necessary for clari®cation. (b) Cochrane Database of Systematic Reviews. Pharmacologic treatment of acute spinal cord injury. 9 (c) Additional manual searching using the reference lists from recent publications, cross checking with previous reviews and personal reference ®les.
Study selection
Articles reporting primary data satisfying the criteria below were selected.
(a) Inclusion criteria 1. Steroid therapy used: high dose (short duration) methylprednisolone, or equivalent dexamethasone, given within hours (maximum 12) following spinal cord injury. 2. Outcome measures reported separately for steroid and non-steroid treated groups. Primary outcome: standardised neurological examination or neurological function; ie admission or pretreatment neurological impairment and post treatment assessment. Secondary outcomes: acute mortality, early morbidity.
(b) Exclusion criteria Questionable validity of the study following evaluation using the criteria below.
Study evaluation
Validity To assess the value of individual clinical studies or publications, the guides published by Guyatt et al 7 (for the Evidence Based Working Group in Canada) for randomised controlled trials were used (listed below).
Readers' Guide for an Article About Therapy
Are the results of the study valid? PRIMARY GUIDES: Was the assignment of patients to treatments randomised? Were all patients who entered the trial properly accounted for and attributed at its conclusion? Was follow-up complete? Were patients analyzed in the groups to which they were randomised? SECONDARY GUIDES:
Were patients, health workers and study personnel`blind' to treatment? Were the groups similar at the start of the trial? Aside from the experimental intervention, were the groups treated equally?
WHAT WERE THE RESULTS?
How large was the treatment eect? How precise was the estimate of the treatment eect?
WILL THE RESULTS HELP ME IN CARING FOR MY PATIENT?
Can the results be applied to my patient care? Were all clinically important outcomes considered? Are the likely treatment bene®ts worth the potential harms and costs?
Comparable aspects of cohort studies were assessed in a similar manner, following the methodology of a review of the treatment of malignant extradural spinal cord compression by Loblaw and Laperriere 10 (listed below).
Were the inception cohort criteria described (case control, historical, contemporary)?
Were attempts made to select all those ®tting these criteria?
What were the potential sources of bias?
Were the cohorts of patients demonstrably similar?
Was each cohort treated in a similar manner? were they treated at the same institution(s)? were outcomes measured the same way in each cohort? Recommendation criteria A There is good evidence (level I) to support the recommendation that the manoeuvre be speci®cally considered as an intervention for the condition. B There is fair evidence (level II) to support the recommendation that the manoeuvre be speci®cally considered as an intervention for the condition. C There is poor evidence (level III) that the manoeuvre be speci®cally considered as an intervention for the condition or it confers no advantage over competing interventions. D There is fair evidence (level II) to support the recommendation that the manoeuvre be excluded from considerations as an intervention for the condition. E There is good evidence (level I) to support the recommendation that the manoeuvre be excluded from consideration as an intervention for the condition.
Spinal cord injury evaluation ± established prognostic factors in acute spinal cord injury Survival and early mortality Early mortality is related to age and measures of injury severity such as neurological level, degree of injury completeness and ventilator dependency.
± 13
Using multivariate analysis (Cox model), a prospective study of 157 ASCI patients found independent predictors of survival to be age (P50.0001), initial conscious level (P50.03) and respiratory assistance (P50.002). 13 Injury severity scoring systems can be correlated with early mortality risk. 14 The initial extent of spinal cord  dysfunction is the main predictor for neurological  outcome. 12,15 ± 17 The pattern of neurological improvement is related to both the level at which the cord is damaged and completeness of the de®cit. 15, 16 Animal studies ± experimental acute spinal cord injury Study designs, models of cord injury, treatment regimes, duration of follow up, functional assessments and outcomes were extracted and summarised. This process was undertaken for larger animal models initially. Criteria for further evaluation were not available and it was considered inappropriate to extend this to rat/mouse/rabbit studies.
Neurological outcome

Results
MEDLINE search
The unrestricted search strategy identi®ed a large number of references which were excluded from further consideration. These included 37 review format articles, six editorials or commentaries, ten letters, six clinical series, one reference on clinical pharmacology and 11 references to steroid side eects.
The reference and abstract of experimental SCI publications were reviewed and the following excluded. Twenty-two animal studies used non inclusion criteria steroid regimes (1971 ± 1996) . Fourteen references to larger animal model ASCI studies did not contain neurological outcomes. Thirty-six small animal ASCI model publications (majority used rats, published 1968 ± 1999) contained 12 with functional outcome measures (published 1990 ± 1998). Of these 12 abstracts, half appeared to indicate positive results, the remainder negative.
Clinical trials and cohort studies
Level of evidence and primary outcome results
Three clinical trials and six cohort study publications were identi®ed which satis®ed the inclusion and validity criteria for this review. Of those considered closely but excluded, a large clinical series by Kiwerski One-hundred-and-six patients were entered, ®ve died during the follow up period, one refused to attend for follow up consultation. All the other patients were reviewed at 1 year post injury and analysed in the groups to which they had been randomised (ie intention to treat).
Secondary criteria Neurological assessment (ASIA score) on admission and 1 year later was performed by one experienced neurologist blind to the treatment given. The four treatment groups did not dier in terms of age, initial Glasgow Coma Scale, Injury Severity Score, delay between accident and administration of treatment or ASIA scores (total motor, pinprick and touch scores). All patients were otherwise managed similarly at a single centre; recruitment lasted from November 1990 to March 1995. A policy of early surgery was also followed: 80 patients (76%) were operated on within 24 h, 49 of which were performed within 8 h of injury.
This study met the primary validity criteria of Guyatt et al. 7 Neurological assessment was blind, although patients and health workers may not have been. Otherwise secondary criteria were met.
Primary outcome results Ordinal data was reported as median and 25th, 75th centiles and compared using the Kruskal-Wallis test. Initial and 1 year total ASIA scores diered signi®cantly (P50.001) for all ASIA scores and treatment groups. One year scores did not dier between the four treatment groups. Two way ANOVA showed no evidence of interaction between MPSS and Nimodipine; 1 year scores did not dier between 54 patients receiving MPSS and 52 not given steroids. A total of 487 patients were randomly assigned to treatment groups: subsequently 15 were de®ned as randomised, not eligible; 16 as protocol violations eligible; mortality was reported graphically as survival probability curves. Eighty-eight per cent of patients entered, ie 427 or 95% of the surviving patients had a 1 year neurological examination. Patients were initially analyzed by the groups to which they were randomised.
Secondary criteria All phases of the study were carried out in a blinded fashion. Clinical assessments were carried out by research nurse(s) at each centre on admission and at 6 weeks, 6 months and 1 year post injury. Demographic and clinical characteristics of the patients at study entry did not dier among the three treatment groups. Patients were recruited from14 May 1985 to 18 December 1988 through ten study centres (contributing between 11 and 103 patients per centre). 42.2% (Naloxone) ± 48.8% (Methylprednisolone) of patients were admitted to the study centre direct. Surgery was not performed in 57 (Naloxone), 65 (MPSS), 67 (Placebo) of the treatment groups, ie about 60% overall underwent surgery. 23 The study design of NASCIS 2 ensured the primary validity criteria of randomisation and secondary criteria of`blinding' were met. Treatment groups were similar at the start. Follow up completeness and variations arising from multicentre participation, in terms of numbers of patients per centre, SCI care systems and assessors pose some questions about possible compromise to validity.
Primary outcomes Patients were examined on admission, at 6 weeks, 6 months and 1 year using a standardised neurologic system. Motor strength was scored on the standard clinical scale of 0 ± 5 in 14 muscle groups and summed (0 ± 70 points). Pin and touch sensation were scored on a scale of 1 ± 3 in 29 dermatomes (1 indicates no, 2 is abnormal and 3 normal sensation). Analysis of scores used data from examination of the right side of the body. The primary end point was a change in neurologic function between baseline and follow up examination. Analysis of variance was used to test the hypothesis that the change in score was not dierent across the three treatment groups.
Initial motor and sensory scores are presented as means+SD'. Change in neurologic measures are presented as`change in score (P value)'. The change in score numbers are not speci®cally de®ned in the text (eg as a mean value) nor are measures of spread such as standard deviation given.
Primary outcome results (randomised treatment groups) No eect on motor scores was reported at any time. The sensory scores happened to reach statistical signi®cance only at 6 months but not at 6 weeks or 1 year. The results, for intention to treat randomised groups, are quoted verbatim below:
Six weeks (42 ± 49 days) follow up data: 1 Considering all the patients 6 weeks after injury, we found that the scores of those treated with methylprednisolone improved more than the scores of those given placebo for the sensations of pinprick (change from admission score, 6.7 vs 4.8, P=0.079) and touch (6.1 vs 3.9; P=0.066). No comparable improvements in motor function were observed'.
Six months (180 ± 210 days) follow up data: 1 After 6 months the patients treated with methylprednisolone had greater sensory improvement than those receiving placebo (pinprick, 10.0 vs 6.6; P=0.012; and touch 8.7 vs 5.9; P=0.042)'.
One year follow up data (365 ± 425 days after injury): 17 Considering all randomised patients at 1 year, there were no signi®cant dierences in the neurological function by the treatment group, although patients treated with methylprednisolone showed a slight advantage over those receiving placebo on all three neurological parameters'.
Level II-1 evidence: well designed controlled trials without randomisation Japanese study: (Otani et al 24 ) (Exclusions were made after randomisation which limits the inferences which can be drawn and precludes inclusion of this trial as Level I evidence).
Patients were assigned to receive methylprednisolone or standard treatment using a four envelope process (two for MPSS, two no MPSS). One-hundredand-®fty-eight patients were entered, 12 in the MPSS and 29 in the control group were excluded. Among the MPSS group, the reasons were inappropriate dose (six), other steroid usage (two), inappropriate neurological examination (one), no neurological de®cit (one) and inappropriate subject (two). Among the control group the reasons were: usage of steroid more than 100 mg of MPSS before the treatment protocol started (®ve), usage of steroid within 5 days of injury (14) , inappropriate selection (three), death (three) and others (four). Only one patient was lost to follow up who was excluded. Seventy patients treated with methylprednisolone and 47 controls were studied. Results were presented for these groups by complete/ incomplete subgroups. The two treatment groups diered signi®cantly on admission in terms of Frankel grade and pinprick and motor total scores. This was conducted as a multicentre study following, in part, the methodology of NASCIS 2, no information about surgery was published. Admission; 24, 48, 72 h; 1, 6 week, 3 and 6 month assessments were reported.
This study was in practice not eectively randomised and observers were not blinded, but prospective, virtually complete, detailed follow up was reported. However the control group was allowed an alternative steroid ± equivalent to 100 mg/day MPSS (maximum total 500 mg over 7 days).
Outcomes reported For the two patient groups, graphical change in recovery scores are published which show virtually identical changes in sensory scores to 6 weeks, with relative plateauing in the placebo group thereafter to produce a dierence of approximately 3 points at 6 months. Motor scores diverge slightly by approximately 4 points at 6 months. None of these were signi®cant.
Recovery by segment as complete/partial/no recovery is also reported. Seventy-one consecutive admissions with acute spinal cord injury to the National Spinal Trauma Unit, Dublin, Ireland between June 1991 and December 1994 were reviewed retrospectively. Five had died, three emigrated leaving 63 available for follow up 13 to 57 months post injury. Thirty-eight patients received MPSS, 25 who did not were referred more than 8 h after injury. Admission and latest follow up ASIA scores were analyzed overall and presented by four paraplegia/tetraplegia and complete/incomplete subgroups.
This study was undertaken`to determine the factors in¯uencing neurological recovery'.`In this study no statistically signi®cant outcome advantage was seen in any group of spinal cord injury patients that received corticosteroids'.
Gerhardt: 26
Three-hundred-and-sixty-three spinal cord injury survivors from two time periods (May 1990 ± December 1991 and January to December 1993) following dissemination of NASCIS 2 conclusions were identi®ed from Colorado's comprehensive population based spinal cord injury surveillance data. Their records were reviewed for documentation of steroid usage. Frankel grades were assigned to the documented neurological preservation on admission. Discharge Frankel grades were based on neurological status reported at the end of the patients' initial inpatient rehabilitation (or discharge to home). In 188 use of NASCIS 2 protocol was documented, in 90 no MPSS or other steroid, in 47 incorrect or unknown dosage of MPSS, in 14 other or unspeci®ed steroid and 24 records contained insufficient data.
The strength of this study lies in being from rigorous population based data. Potential biases from the involvement of 24 hospitals diering in steroid utilisation if not other aspects of treatment and hospital record derived neurological status is acknowledged. One and two Frankel grade improvements by initial Frankel grade are tabulated for all the patients reported.`There were no signi®cant dierences in neurological outcomes, using the Frankel classi®cation system, between those who received the protocol (NASCIS 2) and those who did not' (ie those who did not receive any steroids).
Level II
MPSS and no steroid groups did not dier by age or injury severity score. Neurological outcome was not detailed, the study was`undertaken to de®ne the adverse eects that MPSS has on patients with multiple blunt injuries and ASCI'. Mortality and morbidity during acute hospital stay were documented (see below ± secondary outcomes).
George et al:
28
One-hundred-and-forty-®ve records comprising all trauma registry SCI admitted to two Level 1 trauma centres between 1989 and 1992 were reviewed. 6.9% were caused by gunshot wounds, 60% motor vehicle accidents, 15% falls, 6.9% diving. Ten patients had died, three records contained incomplete information, two patients were treated with steroids for other conditions. Methylprednisolone treatment was`routinely applied to SCI in the middle time frame of the study'. Seventy-®ve methylprednisolone treated patients were compared to 55 not given steroids (historical controls).`Data were analyzed by students' t-test, Mann-Whitney test and Chi-square analysis with P50.05 assigned signi®cance'. Similar trauma care was given except for MPSS, overall hospital length of stay averaged 20 days. Signi®cant dierences were reported for mean age (MPSS 30, no steroid 38 years) and injury severity scores (MPSS 24, no steroid 31) on admission.
Assessment was made of motor strength and sensory de®cit change between admission and discharge, and categorised as improvement, deterioration or no change. However no details of the neurological examination were given. Using this methodology there was no signi®cant dierences between MPSS and no steroid groups; ®ve MPSS and two no steroid patients developed deterioration of neurologic function during hospitalisation'.
Mobility was assigned upon admission and discharge according to a 6 point scale (6=dependent, 5=self care assisted, 4=wheelchair assisted, 3=wheelchair independant, 2=ambulatory assisted, 1=no assistance required). Admission scores were similar (MPSS group 5.99 vs no steroid group 5.90) but diered signi®cantly on discharge from the acute hospital (MPSS 5.16, no steroid 4.67, P50.05). Despite the older average age and higher injury severity score the non-steroid group had better mobility on acute hospital discharge.
Level II-3 evidence ± penetrating injuries: Two-hundred-and-®fty-two records satisfying the inclusion criteria: single penetrating spinal cord injury, no head injury, admission CT scan available, all care provided within system; were reviewed retrospectively. Sixteen utilising non-NASCIS 2 steroid protocol were excluded. No steroid recipients numbered 181, from March 1980 to 1990; 55 received NASCIS 2 protocol MPSS between 1990 and July 1993. Frankel scores at admission and de®nitive discharge from the SCI care system were compared.`The hypothesis that methylprednisolone therapy signi®cantly improves functional outcomes in patients with gunshot wound injuries to the spine was rejected'.
Secondary outcomes:
Acute mortality, early morbidity, duration of ventilation and intensive care stay Mortality and particularly morbidity details are not reported with any consistency and there is a general lack of diagnostic de®nitions. Few signi®cant differences emerge from what is published. Table 1 provides a summary, excluding those publications about penetrating injuries only.
Incidence of pneumonia, duration of ventilation and intensive care length of stay were signi®cantly more for methylprednisolone treated patients in the experience of Gerndt et al, 27 the dierences being more marked in those not undergoing surgery (22% of MPSS and 25% of non-steroid groups had no surgery).
Petitjean et al 22 reported that hyperglycaemia appeared as a complication speci®c to treatment with MPSS. Duration did not exceed 72 h however intravenous insulin was necessary. Motor recovery appeared less good in patients treated with corticosteroids who had an initial hyperglycaemia (ASIA m 1 =56 vs 62) but the dierence was not signi®cant.
Treatment recommendations linked to evidence:
Recommendations linked to the level of evidence, according to the frameworks above, are summarised for studies with longer term neurological examination outcomes and reasonable study validity 1,17,22,24 ± 26,28 ± 30 ( Table 2 ). They provide a small body of evidence for no signi®cant bene®cial treatment eect from high dose methylprednisolone (rather than lack of evidence for an eect). Weaker evidence (level II-3) from George et al 28 would suggest a negative eect of MPSS on the short term outcome of mobility score reported in their study.
Animal studies of experimental spinal cord injury:
Twelve publications, satisfying the selection critieria for primary data, high dose steroid treatment and neurological function outcome were found.
31 ± 34 Two appear to describe remarkably similar experimental Notes: *, signi®cantly dierent (P<0.05). Gerndt ± numbers in (italics) apply to patients not operated on, ie 22% of MPSS and 25% of no steroid group. M, MPSS=methylprednisolone; N=nimodipine; P=placebo; MI=myocardial infarction; CVS=cardiovascular system, (cardiac) arrest. Duration: mean+SD days.
animals. 34, 35 The primary data criteria was not strictly met by a publication by Young et al 43 in which theỳ describe here extended experimental studies carried out in our laboratory over the past 5 years, evaluating the aects of high dose NLX (naloxone) and MP (methylprednisolone) administered 45 min after spinal cord injury in cats'. Under`statistical analyses', these authors state:`some animals were prospectively eliminated from the study, for example, cats that recovered SEP prior to the administration of treatments were excluded from the study'. What eect this has on their results is not known. Concern about the validity and functional signi®cance of results applies to other studies. The neurological rating used by Green et al 31 would be critically dependent on the precision of the level of the cord lesion (as opposed to the severity).
The`recovery index' 33 ± 35 summates ordinal scores for overlapping abilities; ie mobility, running, stairs, making the progression of total score relative to change in neurological impairment questionable. Parametric statistics are inappropriately used to analyse this summed ordinal' data and other ordinal scales. 33, 35, 38 The eect of morbidity and mortality on experimental outcome is not generally analysed; ill cats were removed from one study 35 or dead cats replaced in others. 39, 40 In Table 3 the publications are grouped by reported outcome. Those with authors and animal model in common are listed together. The weight of evidence lies with those studies demonstrating no de®nite eect of MPSS on functional outcome. In cat experiments with higher level cord damage, deaths in the MPSS treated groups are notable. Eight treated (experimental) and eight untreated (control) were followed as pairs. An additional eight animals (experimental) were injured and treated but were not paired* 
Safety and side eects of methylprednisolone
The weight of evidence with regard to mortality and morbidity provided by these studies is much weaker. They cannot reliably provide reassurance of safety. They provide weak evidence, in themselves, of some increase in complications, particularly infection related. Concern about lack of information on the risk side is underlined by the fact that randomised controlled trials, of necessity, involve selected populations. Comparison between NASCIS 2 morbidity 1,17 and the model system outcomes 11 in America and the study of Petitjean 22 with the paper on survival 13 from the same hospital some years previously serve to substantiate this concern. The pro®le of potential steroid related side eects and causes of mortality/ morbidity in acute spinal cord injury overlap, making their detection dicult.
Publications excluded by review criteria
The papers considered and excluded from this review would not substantially alter our conclusions. Kiwerski 18 advocates use of dexamethasone (low dose) based on his clinical review of 269 cases (1976 ± 1990) but notes some increase in the incidence of complications such as gastrointestinal bleeding and delayed wound healing. Gabler 20 concluded from their experiencè that methylprednisolone therapy in penetrating ASCI may impair recovery of neurologic function'. The paper contained ®gures for neurologic assessments at 1 week from two-thirds of the 31 penetrating injury cases discussed, with the follow-up to 2 months post injury reported to show similar ®ndings. 
NASCIS 2
What did NASCIS 2 show? Subgroup analysis can bè both informative and misleading' according to Oxman and Guyatt. 5 The subgroups analyzed resulted from subdivision by initial (emergency room designated) neurological impairment category and by time of administration post injury.
1`T he 8 h criterion was based on the median treatment time that divided the patient population into approximately equal halves' (Young and Bracken 45 ). Information on outcome for all the subgroups was only published in 1993 in terms of`recovery of lost function', which was calculated from the expanded neurological scores. 46 Information for MPSS and placebo treated patients has been extracted from the 1993 46 and from the 1990/1992 1, 17 publications (Table 4) . Examination of these published results is informative, the data contain two obvious phenomena in terms of change in motor function produced by the time of administration subgroupings: grossly dierent pre and post 8 h incomplete neurology placebo treated groups 46 and a relatively large`step up' in neurological scores at 6 weeks in the pre 8 h MPSS treated complete group. 1, 17, 46 (There is subsequent parallel/ converging change relative to the other treatment groups). Neither of these constitute a rational treatment eect. Added together they constitute the dierence between the MPSS and placebo pre 8 h post injury administration subgroups.
The ®gures, given for patients designated incomplete initially, endorse strong consideration of chance com=complete. *, **, *** indicate signi®cantly dierent comparisons between the two within 8 h subgroups reported by Bracken et al. 17, 46 No comparisons reported between same treatment, dierent time of administration subgroups subgroupings and`time dependent eect' in¯uences other than the treatments given. The`best' improvement in motor function below the lesion is seen in those given placebo after 8 h post injury, no treatment group does quite as well with MPSS after 8 h the worst. (Figure 6 , page 505, Bracken and Holford 46 ).
Study design and statistical concerns
None of the trials reported here measure up fully to current standards for study design, conduct of trial, analysis and presentation. 47, 48 Many did not include justi®cation of sample size (ie power analysis), were not clear about the method of randomisation 49 and did not include a discussion of clinical vs statistical significance. 5, 8 Furthermore unplanned subgroup analysis, especially where the subgroups are de®ned based on the data and not clinically, can only be used to plan a further con®rmatory trial and cannot be used to derive a gold standard method of treatment. 2, 5 The NASCIS 2 pre 8 h post injury subgroup analysis and results as published in 1990 and 1992 have not been replicated or endorsed by other studies.
Conclusion
Based on the evidence produced by this systematic review the use of high dose methylprednisolone in the management of acute spinal cord injury cannot be supported. A deleterious eect on early mortality and morbidity cannot be excluded by this evidence. Use as a positive control is certainly not justi®ed by the evidence available. Lack of a placebo control group potentially compromises research methodology and progress in the management of acute spinal cord injuries.
